Literature DB >> 10826476

Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand.

S Subbarao1, S Vanichseni, D J Hu, D Kitayaporn, K Choopanya, S Raktham, N L Young, C Wasi, R Sutthent, C C Luo, A Ramos, T D Mastro.   

Abstract

We obtained specimens from 128 HIV-1 seroconverters identified from 1995 through 1998 in a prospective cohort study of 1,209 HIV-negative injecting drug users (IDUs) in Bangkok, Thailand. Epidemiologic data indicated that parenteral transmission accounted for nearly all infections. HIV-1 DNA from the C2-V4 env region was sequenced, and phylogenetic analyses determined that 102 (79.7%) of the specimens were subtype E and 26 (20.3%) subtype B strains. All subtype B strains clustered with strains often referred to in previous studies as Thai B or B'. The interstrain nucleotide distance (C2-V4) within subtype E strains was low (mean, 6.8%), and pairwise comparisons with a prototype subtype E strain, CM244, showed limited divergence (mean, 5.6%). The subtype B stains showed greater interstrain divergence (mean, 9.2%) and were significantly divergent from the prototype B strain HIV-MN (mean, 13.0%; p < 0.0001). The subtype E strains had significantly lower mean V3 loop charge than did subtype B strains (p = 0.017) and, on the basis of analysis of amino acid sequences, were predicted to be predominantly (91%) non-syncytium-inducing (NSI), chemokine coreceptor CCR5-using (CCR5+) viruses. The subtype B strains had a higher mean V3 loop charge, and a smaller proportion (23%) were predicted to be NSI/CCR5+ viruses. This study demonstrates that most incident HIV1 infections among Bangkok IDUs are due to subtype E viruses, with a narrow spectrum of genetic diversity. The characterization of incident HIV-1 strains from 1995 to 1998 will provide important baseline information for comparison with any breakthrough infections that occur among IDUs in Bangkok who are participating in an HIV-1 vaccine efficacy trial initiated in 1999.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826476     DOI: 10.1089/088922200308693

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Identification of a novel HIV type 1 circulating recombinant form (CRF52_01B) in Southeast Asia.

Authors:  Yongjian Liu; Lin Li; Zuoyi Bao; Hanping Li; Daomin Zhuang; Siyang Liu; Xiaolin Wang; Tianyi Li; Lei Jia; Shaomin Yang; Jingyun Li
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-05       Impact factor: 2.205

2.  Molecular epidemiology of HIV type 1 in Singapore and identification of novel CRF01_AE/B recombinant forms.

Authors:  Oon Tek Ng; Supriya Munshaw; Susanna L Lamers; Kuan Kiat Chew; Li Lin; Andrew D Redd; Jordyn Manucci; Thomas C Quinn; Stuart C Ray; Arlene Chua; Yee Sin Leo; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-14       Impact factor: 2.205

3.  Field evaluation of the gag-based heteroduplex mobility assay for genetic subtyping of circulating recombinant forms of human immunodeficiency virus type 1 in Abidjan, Côte d'Ivoire.

Authors:  Souleymane Sawadogo; Christiane Adjé-Touré; Celestin E Bilé; Rene E A Ekpini; Terence Chorba; John N Nkengasong
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

4.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand.

Authors:  Wanitchaya Kittikraisak; Frits van Griensven; Michael Martin; Janet McNicholl; Peter B Gilbert; Rutt Chuachoowong; Suphak Vanichseni; Ruengpung Sutthent; Jordan W Tappero; Timothy D Mastro; Dale J Hu; Marc Gurwith; Dwip Kitayaporn; Udomsak Sangkum; Kachit Choopanya
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

6.  Phylodynamics of HIV-1 from a phase III AIDS vaccine trial in Bangkok, Thailand.

Authors:  Marcos Pérez-Losada; David V Jobes; Faruk Sinangil; Keith A Crandall; Miguel Arenas; David Posada; Phillip W Berman
Journal:  PLoS One       Date:  2011-03-10       Impact factor: 3.240

7.  Methods used for successful follow-up in a large scale national cohort study in Thailand.

Authors:  Sam-Ang Seubsman; Matthew Kelly; Adrian Sleigh; Janya Peungson; Jaruwan Chokkanapitak; Duangkae Vilainerun
Journal:  BMC Res Notes       Date:  2011-05-27

8.  Assessment of BED HIV-1 incidence assay in seroconverter cohorts: effect of individuals with long-term infection and importance of stable incidence.

Authors:  Janet M McNicholl; J Steven McDougal; Punneeporn Wasinrapee; Bernard M Branson; Michael Martin; Jordan W Tappero; Philip A Mock; Timothy A Green; Dale J Hu; Bharat Parekh
Journal:  PLoS One       Date:  2011-03-04       Impact factor: 3.240

Review 9.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

10.  HIV Incidence and Risk Behaviours of People Who Inject Drugs in Bangkok, 1995-2012.

Authors:  Michael Martin; Suphak Vanichseni; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Punnee Pitisuttithum; Jaranit Kaewkungwal; Frits van Griensven; Janet M McNicholl; Jordan W Tappero; Timothy D Mastro; Somyot Kittimunkong; Kachit Choopanya
Journal:  EClinicalMedicine       Date:  2019-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.